Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085437 (
bacterial meningitis
)
4,038
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
IL-16
is an immunomodulatory cytokine that is characterized by chemotactic activity and stimulation of proinflammatory cytokine expression in monocytic cells. We studied
IL-16
using ELISA in children with meningitis. When meningeal symptoms existed,
IL-16
levels were high in the cerebrospinal fluid (CSF) of both bacterial (939 +/- 877 ng/l, n = 20) and aseptic (341 +/- 371 ng/l, n = 23) meningitis. The values in the CSF were significantly higher than those in non-meningitis controls (29 +/- 8 ng/l, n = 22, P < 0.0001). After meningeal symptoms disappeared,
IL-16
levels in bacterial (191 +/- 149 ng/l, n = 10, P = 0.0042) and aseptic (159 +/- 188 ng/l, n = 13, P = 0.0118) meningitis were lower than those during the symptomatic stage.
IL-16
levels were the highest before day 5 of the illness and then gradually fell. Significant correlations were found between
IL-16
levels and both G-CSF levels (r = 0.783, n = 11, p = 0.0029) and IL-6 levels (r = 0.818, n = 12, P = 0.0005) in the CSF of bacterial and aseptic meningitis.
IL-16
levels in all CSF samples from non-meningitis controls were lower than those in serum. In contrast,
IL-16
levels in the CSF in six of 16 samples from
bacterial meningitis
and two of 18 samples from aseptic meningitis were higher than those in serum. Serum levels of
IL-16
did not fluctuate throughout the course of meningitis. These data indicate that
IL-16
levels rise transiently in CSF at the initial stage of meningitis. We speculate that
IL-16
may promote inflammatory responses during meningitis in concert with other proinflammatory cytokines.
...
PMID:Transient elevation of interleukin-16 levels at the initial stage of meningitis in children. 1260 2